RxDoctor Payments Data

Monica Thomas, PA

Physician Assistant · Nottingham, MDNPI 1013245281

Payments from drug & device makers

$6,995in general payments, 2019–2025

Across 322 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$575
  • Nevro Corp.$479
  • Collegium Pharmaceutical, Inc.$467
  • Averitas Pharma Inc.$462
  • Medtronic$429
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$6,995100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,995 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$334,739
Medicare patients
342
Services billed
18,461

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide11$29,344
Oxycodone Hcl1,349$24,553
Buprenorphine68$21,064
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen586$17,250
Xtampza ErOxycodone Myristate43$16,139
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen402$10,480
MovantikNaloxegol Oxalate16$7,954
Hysingla ErHydrocodone Bitartrate16$7,598
Pregabalin227$6,226
Gabapentin450$4,836
BelbucaBuprenorphine Hcl12$4,740
OxycontinOxycodone Hcl16$4,738
Lidocaine61$4,468
Morphine Sulfate ErMorphine Sulfate171$3,411
Celecoxib76$3,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$575$29,34411 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$467$20,87955 claims
Redhill Biopharma Inc.Movantik$25$7,95416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Nottingham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →